AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) has announced the completion of a public offering of 10,000,000 shares of common stock. The offering included 1,500,000 shares that were sold pursuant to a full exercise of an over-allotment option granted to the underwriters. The net proceeds of the offering totaled $26.6 million. The proceeds will be used for general working capital. They may also be used to further clinical, regulatory, and commercial development of Zenvia. The sole book running manager of the offering is Jefferies & Company, Inc. the co-manager was Canaccord Adams, Inc.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
Avanir Pharmaceuticals, Inc. (Avanir) is a pharmaceutical company focused on acquiring, developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company’s lead product candidate, Zenvia (dextromethorphan hydrobromide/quinidine sulfate), has completed three Phase III clinical trials for the treatment of pseudobulbar affect (PBA) and has completed a Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain (DPN pain). In addition to its focus on products for the central nervous system, Avanir also has a number of partnered programs in other therapeutic areas. Its product, docosanol 10% cream, (sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA).
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
